Macrophage Migration Inhibitory Factor Stimulates Angiogenic Factor Expression and Correlates With Differentiation and Lymph Node Status in Patients With Esophageal Squamous Cell Carcinoma
暂无分享,去创建一个
Xin Huang | Michael Bacher | Yi Ren | Simon Law | S. Law | J. Wong | G. Srivastava | Xin Huang | M. Bacher | Yi Ren | John Wong | Gopesh Srivastava | Ping Yin Lee | Pin-Yin Lee
[1] T. Kuroki,et al. Molecular and cellular features of esophageal cancer cells , 2005, Journal of Cancer Research and Clinical Oncology.
[2] L. Sobin,et al. TNM classification: clarification of number of regional lymph nodes for pN0 , 2001, British Journal of Cancer.
[3] Y. Ozeki,et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma , 1997, Cancer.
[4] R. Bucala,et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.
[5] H. Matsubara,et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma , 2001, Cancer.
[6] D. Schadendorf,et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. , 1993, Journal of immunology.
[7] G. Hannon,et al. A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.
[8] J. Bernhagen,et al. MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.
[9] K. Tracey,et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.
[10] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[11] R. Atkins,et al. Macrophage migration inhibitory factor expression in human renal allograft rejection. , 1998, Transplantation.
[12] Michael Bacher,et al. Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma , 2003, International journal of cancer.
[13] S. Fan,et al. Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study , 2001, Annals of surgery.
[14] Sobin Lh. TNM classification: clarification of number of regional lymph nodes for pN0. , 2001 .
[15] S. Todo,et al. An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. , 2000, Cytokine.
[16] M. Feith,et al. Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients , 2000, Annals of surgery.
[17] M. Suzuki,et al. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. , 1999, Biochemical and biophysical research communications.
[18] M. Kitajima,et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] H. Dosaka-akita,et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung , 2000, Cancer.
[20] M. Burdick,et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. , 1996, The Journal of clinical investigation.
[21] C. Lau,et al. De Novo Expression of Macrophage Migration Inhibitory Factor in Atherogenesis in Rabbits , 2000, Circulation research.
[22] M. Tachibana,et al. Prognostic Significance of Fas and Fas Ligand System-Associated Apoptosis in Gastric Cancer , 2000, Annals of Surgical Oncology.
[23] K. Chu,et al. Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal Cancer: Impact of Chemoradiation and Change in Treatment Strategy , 2003, Annals of surgery.
[24] K. Chayama,et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)‐C in human esophageal squamous cell carcinomas , 2001, International journal of cancer.
[25] Y. Furukawa,et al. Inactivation of the p53 protein in cell lines derived from human esophageal cancers , 1997, International journal of cancer.
[26] L. Friedman,et al. Adenocarcinoma of the Esophagogastric Junction , 1999, Digestive Diseases.
[27] Atkins,et al. Up‐regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat , 1999, Clinical and experimental immunology.
[28] J. Wong,et al. Prognostic implication of proliferative markers MIB‐1 and PC10 in esophageal squamous cell carcinoma , 1996, Cancer.
[29] Barbara Magi,et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue , 1997, Electrophoresis.
[30] S. Law,et al. Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: A prospective clinico‐pathological study and survival analysis of 70 patients , 1997, International journal of cancer.
[31] Simon Law,et al. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients , 1999, American Journal of Gastroenterology.
[32] J. Bernhagen,et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.
[33] R. Atkins,et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. , 2000, Kidney international.
[34] E. Ma,et al. Establishment and characterization of HKESC-1, a new cancer cell line from human esophageal squamous cell carcinoma. , 2000, Cancer genetics and cytogenetics.
[35] R. Bucala,et al. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). , 2000, Seminars in cancer biology.
[36] R. Bucala,et al. An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma , 1999, Molecular medicine.
[37] S. Law,et al. Establishment, characterization, karyotyping, and comparative genomic hybridization analysis of HKESC-2 and HKESC-3: two newly established human esophageal squamous cell carcinoma cell lines. , 2002, Cancer genetics and cytogenetics.
[38] K. Meyer-Siegler,et al. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. , 1996, Urology.
[39] M. Tachibana,et al. Spontaneous apoptosis in advanced esophageal carcinoma: its relation to Fas expression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] R. Holmdahl,et al. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. , 1997, Journal of immunology.
[41] M. Furihata,et al. Prognostic significance of human papillomavirus genomes (type‐16, ‐18) and aberrant expression of p53 protein in human esophageal cancer , 1993, International journal of cancer.
[42] Y. Yang,et al. Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. , 2000, The Journal of clinical endocrinology and metabolism.
[43] S. Natsugoe,et al. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. , 1995, Cancer research.